UBS Group’s IVERIC bio, Inc. Common Stock ISEE Stock Holding History

UBS Group’s Portfolio ISEE Stock Details ISEE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Sell	-543,600	Closed	-$21.4M	–	10347
2023 Q2	$21.4M	Buy	543,600 +473,600	+677%	+$16.7M	0.01%	1403
2023 Q1	$1.7M	Buy	+70,000	New	+$1.53M	﹤0.01%	3592
2017 Q1	–	Sell	-10,000	Closed	-$48K	–	8093
2016 Q4	$48K	Buy	+10,000	New	+$297K	﹤0.01%	5868
2016 Q2	–	Sell	-100,000	Closed	-$4.23M	–	8046
2016 Q1	$4.23M	Buy	+100,000	New	+$5.1M	﹤0.01%	2015
2015 Q3	–	Sell	-50,000	Closed	-$2.6M	–	8719
2015 Q2	$2.6M	Buy	50,000 +49,700	+16,567%	+$2.47M	﹤0.01%	2723
2015 Q1	$14K	Buy	300 +200	+200%	+$10.4K	﹤0.01%	7371
2014 Q4	$4K	Buy	+100	New	+$4.2K	﹤0.01%	9143

UBS Group's ISEE Position: Q3 2023 in Review

UBS Group sold out of IVERIC bio, Inc. Common Stock (ISEE) in Q3 2023, closing a stake of 10,431 shares — an estimated $410K sold.

UBS Group first reported a position in ISEE in Q4 2014 and held it in 35 quarters. The position peaked at $5.79M in Q4 2022. 0 funds tracked by Wall St. Rank hold ISEE as of Q3 2023.

UBS Group reported no remaining IVERIC bio, Inc. Common Stock position as of Q3 2023 after selling out during the quarter.
UBS Group sold 10,431 IVERIC bio, Inc. Common Stock shares in Q3 2023, an estimated $410K.
UBS Group first reported a position in IVERIC bio, Inc. Common Stock in Q4 2014 and held it in 35 quarters.
UBS Group's IVERIC bio, Inc. Common Stock position peaked at $5.79M in Q4 2022.
0 funds tracked by Wall St. Rank held IVERIC bio, Inc. Common Stock as of Q3 2023.

Based on UBS Group's 13F filing for Q3 2023, filed 9 Nov 2023.